CK2-Mediated Hyperphosphorylation of Topoisomerase I Targets Serine 506, Enhances Topoisomerase I-DNA Binding, and Increases Cellular Camptothecin Sensitivity

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Bandyopadhyay, Keya ^a   Li, Pingchuan ^a   Gjerset, Ruth A ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CASEIN KINASE II; DNA TOPOISOMERASE; EPITOPE; PLASMID DNA; RECOMBINANT PROTEIN; SERINE; SERINE 506; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA SUPERCOILING; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT TRANSFORMATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CASEIN KINASE II; CELL LINE, TUMOR; DNA FRAGMENTATION; DNA TOPOISOMERASES, TYPE I; DNA, SUPERHELICAL; DRUG RESISTANCE, NEOPLASM; EPITOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORYLATION; PLASMIDS; SERINE; TOPOISOMERASE I INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869803372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050427     Document Type: Article

References (52)

1. Pommier Y, Pourquier P, Fan Y, Strumberg D, (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1400: 83-105.
2. Wang JC, (1996) DNA topoisomerases. Annu Rev Biochem 65: 635-692.
3. Champoux JJ, (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70: 369-413.
4. Tsao YP, Russo A, Nyamuswa G, Silber R, Liu LF, (1993) Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53: 5908-5914.
5. Liu LF, (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375.
6. Bandyopadhyay K, Gjerset RA, (2011) Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 50: 704-714.
7. Bandyopadhyay K, Lee C, Haghighi A, Baneres JL, Parello J, et al. (2007) Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor. Biochemistry 46: 14325-14334.
8. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T, (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930.
9. Dingemans AM, Pinedo HM, Giaccone G, (1998) Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta 1400: 275-288.
10. Larsen AK, Skladanowski A, (1998) Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400: 257-274.
11. Coderoni S, Paparelli M, Gianfranceschi GL, (1990) Phosphorylation sites for type N II protein kinase in DNA-topoisomerase I from calf thymus. Int J Biochem 22: 737-746.
12. Pommier Y, Kerrigan D, Hartman KD, Glazer RI, (1990) Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem. 265: 9418-9422.
13. Turman MA, Douvas A, (1993) A casein kinase type II (CKII)-like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase I. Biochem Med Metab Biol. 50: 210-225.
14. Hackbarth JS, Galvez-Peralta M, Dai NT, Loegering DA, Peterson KL, et al. (2008) Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. J Biol Chem. 283: 16711-16722.
15. Coderoni S, Paparelli M, Gianfranceschi GL, (1990) Role of calf thymus DNA-topoisomerase I phosphorylation on relaxation activity expression and on DNA-protein interaction. Role of DNA-topoisomerase I phosphorylation. Mol Biol Rep 14: 35-39.
16. Trembley JH, Wang G, Unger G, Slaton J, Ahmed K, (2009) Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 66: 1858-1867.
17. Staron K, Kowalska-Loth B, Nieznanski K, Szumiel I, (1996) Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism. Carcinogenesis 17: 383-387.
18. Staron K, Kowalska-Loth B, Zabek J, Czerwinski RM, Nieznanski K, et al. (1995) Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells. Biochim Biophys Acta 1260: 35-42.
19. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, et al. (2001) Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 276: 15537-15546.
20. Roecklein BA, Torok-Storb B, (1995) Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 85: 997-1005.
21. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850-858.
22. Reikhardt BA, Kulikova OG, Borisova GY, Aleksandrova IY, Sapronov NS, (2003) Status of the "protein kinase CK2-HMG14" system in age-related amnesia in rats. Neurosci Behav Physiol 33: 799-804.
23. Olnes MI, Kurl RN, (1994) Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques 17: 828-829.
24. Lee C, Smith BA, Bandyopadhyay K, Gjerset RA, (2005) DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 65: 9834-9842.
25. McConaughy BL, Young LS, Champoux JJ, (1981) The effect of salt on the binding of the eucaryotic DNA nicking-closing enzyme to DNA and chromatin. Biochim Biophys Acta 655: 1-8.
26. Soe K, Dianov G, Nasheuer HP, Bohr VA, Grosse F, et al. (2001) A human topoisomerase I cleavage complex is recognized by an additional human topisomerase I molecule in vitro. Nucleic Acids Res 29: 3195-3203.
27. Stevnsner T, Mortensen UH, Westergaard O, Bonven BJ, (1989) Interactions between eukaryotic DNA topoisomerase I and a specific binding sequence. J Biol Chem 264: 10110-10113.
28. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL, (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370.
29. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG, (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 279: 1504-1513.
30. Soe K, Grosse F, (2003) p53 stimulates human topoisomerase I activity by modulating its DNA binding. Nucleic Acids Res 31: 6585-6592.
31. Rogakou EP, Boon C, Redon C, Bonner WM, (1999) Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol 146: 905-916.
32. Rothenberg ML, (2001) Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond. Oncologist 6: 66-80.
33. National Comprehensive Cancer Network website. Available: www.NCCN.org. Accessed 2012 Oct 25.
34. Wong ET, Berkenblit A, (2004) The role of topotecan in the treatment of brain metastases. Oncologist 9: 68-79.
35. Bomgaars L, Berg SL, Blaney SM, (2001) The development of camptothecin analogs in childhood cancers. Oncologist 6: 506-516.
36. Daya-Makin M, Sanghera JS, Mogentale TL, Lipp M, Parchomchuk J, et al. (1994) Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res 54: 2262-2268.
37. Faust RA, Gapany M, Tristani P, Davis A, Adams GL, et al. (1996) Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. Cancer Lett 101: 31-35.
38. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, et al. (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20: 3247-3257.
39. Lin KY, Tai C, Hsu JC, Li CF, Fang CL, et al. (2011) Overexpression of nuclear protein kinase CK2 alpha catalytic subunit (CK2alpha) as a poor prognosticator in human colorectal cancer. PLoS One 6: e17193.
40. Stalter G, Siemer S, Becht E, Ziegler M, Remberger K, et al. (1994) Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 202: 141-147.
41. Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, et al. (1994) Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 24: 11-16.
42. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, et al. (1995) Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1: 659-666.
43. Laramas M, Pasquier D, Filhol O, Ringeisen F, Descotes JL, et al. (2007) Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 43: 928-934.
44. O-Charoenrat P, Rusch V, Talbot SG, Sarkaria I, Viale A, et al. (2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10: 5792-5803.
45. Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, et al. (1999) Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol 31: 941-949.
46. Shuman S, (1989) Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli. Proc Natl Acad Sci U S A 86: 3489-3493.
47. Shuman S, (1992) DNA strand transfer reactions catalyzed by vaccinia topoisomerase I. J Biol Chem. 267: 8620-8627.
48. Zhu J, Schiestl RH, (1996) Topoisomerase I involvement in illegitimate recombination in Saccharomyces cerevisiae. Mol Cell Biol 16: 1805-1812.
49. Arlt MF, Glover TW, (2010) Inhibition of topoisomerase I prevents chromosome breakage at common fragile sites. DNA Repair (Amst) 9: 678-689.
50. Tuduri S, Crabbe L, Conti C, Tourriere H, Holtgreve-Grez H, et al. (2009) Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol 11: 1315-1324.
51. Ayrault O, Karayan L, Riou JF, Larsen CJ, Seite P, (2003) Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I. Oncogene. 22: 1945-1954.
52. Karayan L, Riou JF, Seite P, Migeon J, Cantereau A, et al. (2001) Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20: 836-848.